Effects of prazosin, atenolol, and thiazide diuretic on plasma lipids in patients with essential hypertension.
The effects of prazosin and atenolol monotherapy on plasma lipid concentrations were compared in 51 patients with mild to moderate essential hypertension. Prazosin monotherapy (mean dose 5.4 +/- 5.3 mg per day) resulted in a significant decrease in total and low-density lipoprotein cholesterol concentrations; these changes were evident at three months and at six to 12 months. Atenolol monotherapy (mean dose 66 +/- 23 mg per day) resulted in a significant increase in plasma triglyceride concentration that persisted during one year of treatment. The deletion of thiazide from the regimen of prazosin plus thiazide resulted in a small stepwise decrease in plasma triglyceride concentration over 12 months of observation. The addition of polythiazide (0.5 mg two to three times weekly) to the regimen of patients in whom acceptable blood pressure was not attained with prazosin or atenolol monotherapy resulted in a decrease in blood pressure, averaging 18.8 mm Hg for systolic and 10.3 mm Hg for diastolic, and a small, though significant, increase in the concentration of low-density lipoprotein cholesterol. It is suggested that the effects of prazosin on plasma lipid composition may be mediated, at least in part, by blocking an action of either the sympathetic nervous system or circulating catecholamines that normally modulate lipoprotein metabolism and might mediate the lipid alterations induced by thiazide diuretics.
D001262:Atenolol / Q000494:pharmacology* / Q000627:therapeutic use; D001581:Benzothiadiazines; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D002986:Clinical Trials as Topic; D004232:Diuretics; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D011224:Prazosin / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism
D001581:Benzothiadiazines; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004232:Diuretics; D008055:Lipids; D049993:Sodium Chloride Symporter Inhibitors; D014280:Triglycerides; D001262:Atenolol; D002784:Cholesterol; D011224:Prazosin